Provexis Funded for Future Growth
Focusing on developing new functional and medical food ingredients and technologies, the company successfully raised funds to accelerate its strategy.
Oct 19 2010 --- Provexis plc, which focuses on the discovery, development and licensing of scientifically-proven functional food, medical food and dietary supplement technologies, has successfully raised significant funds to allow the company to accelerate its strategy of developing new functional and medical food ingredients and technologies.
“Our self-contained business platform spans IP creation and R&D through to clinical trials, commercialisation and regulatory approval. This makes us an attractive collaborative partner for companies seeking growth in the supplements, functional and medical food markets. We’re actively seeking new technologies to acquire and continue to screen a range of possible opportunities”, comments Stephen Moon, Chief Executive.
Provexis is recognised for the quality of its science and regulatory expertise - two areas which remain a key focus for the business. The recruitment of three R&D and formulation scientists adds further depth and knowledge to the experienced management and scientific teams based at the University of Liverpool and the University of Aberdeen’s Rowett Institute of Nutrition and Health.
The technology pipeline continues to strengthen with the extension of the Crohn’s disease trial into two new centres in Edinburgh and Bristol. This move will facilitate a successful conclusion to the trials in 2011 and partnered technology commercialisation. Two further clinical trials will start in early 2011; with the University of Liverpool on hospital superbug Clostridium difficile and with the Institute of Food Research for reduction of cardiovascular inflammation using novel plant-derived extracts.
